The new compounds developed by Vitality belong to a new class of treatments known as cannabinoid prodrugs. Based on the company’s development platform, the cannabinoid compounds are combined with sugar molecules into prodrug formulations. This allows the therapeutically active molecules to … Read More
The post Vitality Biopharma Seeks FDA’s Orphan Drug Status for Cannabinoid Therapy VITA-100 appeared first on Dagga Magazine.